A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172
- 1 October 2009
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 115 (1) , 81-85
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (CA 27469, CA 37517)
This publication has 23 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapyGynecologic Oncology, 2007
- Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancerGynecologic Oncology, 2006
- Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian CancerJournal of Clinical Oncology, 2006
- CA-125 Levels after Surgical Exploration and Radioactive Chromic Phosphate in Ovarian Cancer PatientsGynecologic Oncology, 1996
- Human Peritoneal Mesothelial Cells Are More Potent Than Ovarian Cancer Cells in Producing Tumor Marker CA-125Gynecologic Oncology, 1996
- CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgeryEuropean Journal of Cancer, 1993
- Serum CA125 regression in epithelial ovarian cancer: Correlation with reassessment findings and survivalGynecologic Oncology, 1992
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Reactivity of a monoclonal antibody with human ovarian carcinoma.Journal of Clinical Investigation, 1981